{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:11:10Z","timestamp":1761883870165,"version":"build-2065373602"},"reference-count":100,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.reumae.2021.09.002","type":"journal-article","created":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T22:35:46Z","timestamp":1642026946000},"page":"5-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["2021 clinical practice guidelines for the diagnosis, treatment, and follow-up of patients with peripheral spondyloarthritis. Colombian Association of Rheumatology"],"prefix":"10.1016","volume":"18","author":[{"given":"Lina M.","family":"Saldarriaga-Rivera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilson","family":"Bautista-Molano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Junca-Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s R.","family":"Fern\u00e1ndez-Aldana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel G.","family":"Fern\u00e1ndez-\u00c1vila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego A.","family":"Jaimes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwin A.","family":"J\u00e1uregui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan S.","family":"Segura-Charry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Consuelo","family":"Romero-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar J.","family":"Felipe-Diaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reumae.2021.09.002_bib0005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2010.133645","article-title":"The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general","volume":"70","author":"Rudwaleit","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.09.002_bib0010","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/art.1780341003","article-title":"The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy","volume":"34","author":"Dougados","year":"1991","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reumae.2021.09.002_bib0015","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001136","article-title":"Peripheral spondyloarthritis: a neglected entity \u2014 State of the art","volume":"6","author":"Carron","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.reumae.2021.09.002_bib0020","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/acr.22831","article-title":"Global prevalence of spondyloarthritis: a systematic review and meta-regression analysis","volume":"68","author":"Stolwijk","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.reumae.2021.09.002_bib0025","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.semarthrit.2015.09.001","article-title":"Similarities and differences between patients fulfilling axial and peripheral ASAS criteria for spondyloarthritis: Results from the Esperanza Cohort","volume":"45","author":"del R\u00edo-Mart\u00ednez","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.reumae.2021.09.002_bib0030","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.semarthrit.2018.02.002","article-title":"Dactylitis: a hallmark of psoriatic arthritis","volume":"48","author":"Kaeley","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.reumae.2021.09.002_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/rmdopen-2018-000802","article-title":"Peripheral disease contributes significantly to the level of disease activity in axial spondyloarthritis","volume":"5","author":"De Winter","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.reumae.2021.09.002_bib0040","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s10067-016-3184-2","article-title":"Analysis and performance of various classification criteria sets in a Colombian cohort of patients with spondyloarthritis","volume":"35","author":"Bautista-Molano","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.reumae.2021.09.002_bib0045","first-page":"245","article-title":"Prevalence of rheumatic disease in Colombia according to the Colombian Rheumatology Association (COPCORD) strategy. Prevalence study of rheumatic disease in Colombian population older than 18 years","volume":"25","author":"Londo\u00f1o","year":"2018","journal-title":"Rev Colomb Reumatol"},{"key":"10.1016\/j.reumae.2021.09.002_bib0050","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3899\/jrheum.170520","article-title":"Prevalence of comorbidities and risk factors for comorbidities in patients with spondyloarthritis in Latin america: a comparative study with the general population and data from the ASAS-COMOSPA study","volume":"45","author":"Bautista-Molano","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reumae.2021.09.002_bib0055","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/art.20233","article-title":"The influence of peripheral arthritis on disease activity in ankylosing spondylitis patients as measured with the Bath Ankylosing Spondylitis Disease Activity Index","volume":"51","author":"Heuft-Dorenbosch","year":"2004","journal-title":"Arthritis Rheum"},{"year":"2014","series-title":"Gu\u00eda metodol\u00f3gica para la elaboraci\u00f3n de gu\u00edas de pr\u00e1ctica cl\u00ednica con evaluaci\u00f3n econ\u00f3mica en el Sistema General de Seguridad Social en Salud colombiano","author":"Orden","key":"10.1016\/j.reumae.2021.09.002_bib0060"},{"key":"10.1016\/j.reumae.2021.09.002_bib0065","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.reumae.2021.09.002_bib0070","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction\u2014GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.reumae.2021.09.002_bib0075","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.reumae.2021.09.002_bib0080","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jclinepi.2016.01.032","article-title":"GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health","volume":"76","author":"Sch\u00fcnemann","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.reumae.2021.09.002_bib0085","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jclinepi.2016.09.009","article-title":"GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT","volume":"81","author":"Sch\u00fcnemann","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.reumae.2021.09.002_bib0090","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.09.002_bib0095","first-page":"112","article-title":"Portuguese recommendations for the use of biological therapies in patients with rheumatoid arthritis-2016 update","volume":"42","author":"Duarte","year":"2017","journal-title":"Acta Reumatol Port"},{"key":"10.1016\/j.reumae.2021.09.002_bib0100","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.09.002_bib0105","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/rheumatology\/kew223","article-title":"BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics","volume":"56","author":"Hamilton","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.reumae.2021.09.002_bib0110","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3899\/jrheum.141001","article-title":"2014 Update of the Canadian Rheumatology Association\/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the Management of Spondyloarthritis. Part II: Specific Management Recommendations","volume":"42","author":"Rohekar","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reumae.2021.09.002_bib0115","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jbspin.2013.12.002","article-title":"Recommendations of the French Society for Rheumatology (SFR) on the everyday management of patients with spondyloarthritis","volume":"81","author":"Wendling","year":"2014","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.reumae.2021.09.002_bib0120","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.reumae.2021.09.002_bib0125","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/1756-185X.13510","article-title":"2018 APLAR axial spondyloarthritis treatment recommendations","volume":"22","author":"Tam","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.reumae.2021.09.002_bib0130","unstructured":"Spondyloarthritis in over 16s: Diagnosis and Management. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK553609\/."},{"key":"10.1016\/j.reumae.2021.09.002_bib0135","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.reuma.2019.03.010","article-title":"Recomendaciones del Colegio Mexicano de Reumatolog\u00eda para el manejo de las espondiloartritis","volume":"17","author":"Reyes-Cordero","year":"2019","journal-title":"Reumatol Cl\u00edn"},{"key":"10.1016\/j.reumae.2021.09.002_bib0140","article-title":"Gu\u00eda de Pr\u00e1ctica Cl\u00ednica para el Tratamiento de la Espondiloartritis Axial y la Artritis Psori\u00e1sica","author":"Ca\u00f1ete Crespillo","year":"2015","journal-title":"Soc Esp Reumatol"},{"author":"AGREE Next Steps Consortium","key":"10.1016\/j.reumae.2021.09.002_bib0145"},{"key":"10.1016\/j.reumae.2021.09.002_bib0150","doi-asserted-by":"crossref","first-page":"E839","DOI":"10.1503\/cmaj.090449","article-title":"AGREE II: advancing guideline development, reporting and evaluation in health care","volume":"182","author":"Brouwers","year":"2010","journal-title":"Can Med Assoc J"},{"year":"2019","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","key":"10.1016\/j.reumae.2021.09.002_bib0155"},{"key":"10.1016\/j.reumae.2021.09.002_bib0160","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.reumae.2021.09.002_bib0165","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.reumae.2021.09.002_bib0170","first-page":"29","article-title":"A revised tool for assessing risk of bias in randomized trials","volume":"10","author":"Higgins","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.reumae.2021.09.002_bib0175","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/14737167.2016.1246961","article-title":"How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: data extraction, risk of bias, and transferability (part 3\/3)","volume":"16","author":"Wijnen","year":"2016","journal-title":"Expert Rev Pharmacoeconomics Outcomes Res"},{"key":"10.1016\/j.reumae.2021.09.002_bib0180","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jclinepi.2018.05.011","article-title":"GRADE guidelines: 20. Assessing the certainty of evidence in the importance of outcomes or values and preferences\u2014inconsistency, imprecision, and other domains","volume":"111","author":"Zhang","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.reumae.2021.09.002_bib0185","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.reumae.2021.09.002_bib0190","article-title":"Methotrexate for psoriatic arthritis","volume":"1","author":"Wilsdon","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.reumae.2021.09.002_bib0195","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1186\/1471-2474-15-333","article-title":"Patient participation in decisions about disease modifying anti-rheumatic drugs: a cross-sectional survey","volume":"15","author":"Nota","year":"2014","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.reumae.2021.09.002_bib0200","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3899\/jrheum.140693","article-title":"Facilitators and barriers to adherence in the initiation phase of Disease-modifying Antirheumatic Drug (DMARD) use in patients with arthritis who recently started their first DMARD treatment","volume":"42","author":"Pasma","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reumae.2021.09.002_bib0205","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40273-018-0618-5","article-title":"Cost and cost effectiveness of treatments for psoriatic arthritis: a systematic literature review","volume":"36","author":"D\u2019Angiolella","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.reumae.2021.09.002_bib0210","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/ard.2011.150995","article-title":"A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis","volume":"71","author":"Ash","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.09.002_bib0215","first-page":"1422","article-title":"Therapies for peripheral joint disease in psoriatic arthritis. A systematic review","volume":"33","author":"Soriano","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reumae.2021.09.002_bib0220","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1136\/ard.2008.100008","article-title":"Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis","volume":"68","author":"Hoes","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.09.002_bib0225","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/BOR.0b013e3282f51031","article-title":"The epidemiology of glucocorticoid-associated adverse events","volume":"20","author":"McDonough","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.reumae.2021.09.002_bib0230","first-page":"86","article-title":"Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitis","volume":"33","author":"Zink","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reumae.2021.09.002_bib0235","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/rheumatology\/keh594","article-title":"The cost of glucocorticoid-associated adverse events in rheumatoid arthritis","volume":"44","author":"Pisu","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.reumae.2021.09.002_bib0240","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00296-017-3855-6","article-title":"Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"38","author":"Robson","year":"2018","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.reumae.2021.09.002_bib0245","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2217\/cer-2018-0075","article-title":"Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics\/apremilast: a network meta-analysis","volume":"7","author":"McInnes","year":"2018","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.reumae.2021.09.002_bib0250","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40261-019-00765-w","article-title":"Comparison of the efficacy and safety of tofacitinib and apremilast in patients with active psoriatic arthritis: a bayesian network meta-analysis of randomized controlled trials","volume":"39","author":"Song","year":"2019","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.reumae.2021.09.002_bib0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00393-017-0355-8","article-title":"Relative efficacy and safety of apremilast, secukinumab, and ustekinumab for the treatment of psoriatic arthritis","volume":"77","author":"Song","year":"2018","journal-title":"Z Rheumatol"},{"key":"10.1016\/j.reumae.2021.09.002_bib0260","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00296-017-3919-7","article-title":"Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis","volume":"38","author":"Kawalec","year":"2018","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.reumae.2021.09.002_bib0265","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2474-15-26","article-title":"Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis","volume":"15","author":"Cawson","year":"2014","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.reumae.2021.09.002_bib0270","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.semarthrit.2015.09.004","article-title":"Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: a meta-analysis","volume":"45","author":"Ungprasert","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.reumae.2021.09.002_bib0275","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001117","article-title":"Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis","volume":"6","author":"Ruyssen-Witrand","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.reumae.2021.09.002_bib0280","first-page":"71","article-title":"Assessing the effectiveness of synthetic and biologic disease-modifying antirheumatic drugs in psoriatic arthritis \u2013 a systematic review","volume":"5","author":"Kingsley","year":"2015","journal-title":"Psoriasis (Auckl)"},{"key":"10.1016\/j.reumae.2021.09.002_bib0285","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1111\/jdv.15482","article-title":"Efficacy and safety of systemic treatments in psoriatic arthritis. A systematic review, meta-analysis and GRADE evaluation","volume":"33","author":"Dressler","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.reumae.2021.09.002_bib0290","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/annrheumdis-2020-217163","article-title":"Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis","volume":"79","author":"Kerschbaumer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.09.002_bib0295","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/jdv.16073","article-title":"Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies","volume":"34","author":"Loft","year":"2020","journal-title":"J Eur Acad Dermatology Venereol"},{"key":"10.1016\/j.reumae.2021.09.002_bib0300","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/rheumatology\/ken320","article-title":"The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy","volume":"47","author":"Olivieri","year":"2008","journal-title":"Rheumatology"},{"key":"10.1016\/j.reumae.2021.09.002_bib0305","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.vhri.2019.03.002","article-title":"Cost-effectiveness of secukinumab versus other biologics in the treatment of psoriatic arthritis: an argentinean perspective","volume":"20","author":"Aiello","year":"2019","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.reumae.2021.09.002_bib0310","doi-asserted-by":"crossref","first-page":"S319","DOI":"10.1016\/j.jval.2018.09.1902","article-title":"Pmu66 - Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain","volume":"21","author":"Schweikert","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.reumae.2021.09.002_bib0315","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.09.002_bib0320","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.reumae.2021.09.002_bib0325","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/ard.2007.073569","article-title":"Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period","volume":"66","author":"Conti","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.09.002_bib0330","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/rheumatology\/keq377","article-title":"Efficacy in current practice of switching between anti-tumour necrosis factor- agents in spondyloarthropathies","volume":"50","author":"Paccou","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reumae.2021.09.002_bib0335","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.09.002_bib0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21560","article-title":"Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation","volume":"21","author":"Corbett","year":"2017","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.reumae.2021.09.002_bib0345","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008045","article-title":"Efficacy and safety of immunomodulatory drugs in patients with anterior uveitis: a systematic literature review","volume":"96","author":"G\u00f3mez-G\u00f3mez","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.reumae.2021.09.002_bib0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21680","article-title":"A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults","volume":"21","author":"Squires","year":"2017","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.reumae.2021.09.002_bib0355","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/acr.23329","article-title":"Patients\u2019 attitudes and experiences of disease-modifying antirheumatic drugs in rheumatoid arthritis and spondyloarthritis: a qualitative synthesis","volume":"70","author":"Kelly","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.reumae.2021.09.002_bib0360","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/art.21197","article-title":"Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept","volume":"52","author":"Braun","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reumae.2021.09.002_bib0365","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/ard.2008.092585","article-title":"Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study","volume":"68","author":"Rudwaleit","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.09.002_bib0370","article-title":"Effectiveness of certolizumab pegol in patients with uveitis refractory to other tumor necrosis factor inhibitors. Report of 22 cases [abstract]","volume":"68 Supl 10","author":"Mesquida","year":"2016","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reumae.2021.09.002_bib0375","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s10792-016-0239-y","article-title":"Efficacy of golimumab on recurrent uveitis in HLA-B27-positive ankylosing spondylitis","volume":"37","author":"Yazgan","year":"2017","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.reumae.2021.09.002_bib0380","unstructured":"Calvo-R\u00edo V, Blanco R, Santos-G\u00f3mez M, Rubio-Romero E, Cordero-Coma M, Gallego-Flores A, et al. Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients - ScienceDirect. [Accessed 9 October 2020]. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0049017216000925."},{"key":"10.1016\/j.reumae.2021.09.002_bib0385","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ajo.2016.07.016","article-title":"Anti-TNF\u03b1 treatment for HLA-B27-positive ankylosing spondylitis-related uveitis","volume":"170","author":"Kim","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.reumae.2021.09.002_bib0390","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2019.34.e278","article-title":"The effect of tumor necrosis factor-alpha inhibitors on uveitis in patients with ankylosing spondylitis","volume":"34","author":"Lee","year":"2019","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.reumae.2021.09.002_bib0395","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1016\/S0161-6420(02)01292-7","article-title":"Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis","volume":"109","author":"El-Shabrawi","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1016\/j.reumae.2021.09.002_bib0400","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/annrheumdis-2016-210931","article-title":"Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register","volume":"76","author":"Lie","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.09.002_bib0405","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2147\/PPA.S121032","article-title":"Patient experience with intravenous biologic therapies for ankylosing spondylitis, Crohn\u2019s disease, psoriatic arthritis, psoriasis, rheumatoid arthritis, and ulcerative colitis","volume":"11","author":"Bolge","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.reumae.2021.09.002_bib0410","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.3899\/jrheum.131289","article-title":"Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis","volume":"41","author":"Van Denderen","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reumae.2021.09.002_bib0415","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.3111\/13696998.2012.692341","article-title":"Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents","volume":"15","author":"Gao","year":"2012","journal-title":"J Med Econ"},{"key":"10.1016\/j.reumae.2021.09.002_bib0420","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/acr.23789","article-title":"2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.reumae.2021.09.002_bib0425","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/ajg.2016.7","article-title":"Systematic review and meta-analysis: infliximab or cyclosporine as rescue therapy in patients with severe ulcerative colitis refractory to steroids","volume":"111","author":"Narula","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.reumae.2021.09.002_bib0430","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/apt.12749","article-title":"Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn\u2019s disease","volume":"39","author":"Stidham","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.reumae.2021.09.002_bib0435","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/apt.12644","article-title":"Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis","volume":"39","author":"Stidham","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.reumae.2021.09.002_bib0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20440","article-title":"Comparison of iNfliximab and ciclosporin in steroid resistant ulcerative colitis: pragmatic randomised trial and economic evaluation (construct)","volume":"20","author":"Williams","year":"2016","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.reumae.2021.09.002_bib0445","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/528105","article-title":"Disease activity in psoriatic arthritis: comparison of the discriminative capacity and construct validity of six composite indices in a real world","volume":"2014","author":"Salaffi","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.reumae.2021.09.002_bib0450","first-page":"279","article-title":"Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis","volume":"15","author":"Gisondi","year":"2005","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.reumae.2021.09.002_bib0455","first-page":"819","article-title":"Prevalence of musculoskeletal conditions in an Italian population sample: Results of a regional community-based study. I. The MAPPING Study","volume":"23","author":"Salaffi","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reumae.2021.09.002_bib0460","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/annrheumdis-2017-211998","article-title":"Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort","volume":"77","author":"Van Mens","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.09.002_bib0465","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/acr.23571","article-title":"Burden of psoriatic arthritis according to different definitions of disease activity: comparing minimal disease activity and the disease activity index for psoriatic arthritis","volume":"70","author":"Wervers","year":"2018","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.reumae.2021.09.002_bib0470","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/acr.22204","article-title":"Comparison of composite measures of disease activity in psoriatic arthritis using data from an interventional study with golimumab","volume":"66","author":"Helliwell","year":"2014","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.reumae.2021.09.002_bib0475","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/rheumatology\/kez202","article-title":"The relationship between patient acceptable symptom state and disease activity in patients with psoriatic arthritis","volume":"59","author":"Fei","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reumae.2021.09.002_bib0480","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00296-016-3514-3","article-title":"Disease activity, quality of life and indirect costs of psoriatic arthritis in Poland","volume":"36","author":"Kawalec","year":"2016","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.reumae.2021.09.002_bib0485","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/rheumatology\/keq182","article-title":"Estimation of health care costs as a function of disease severity in people with psoriatic arthritis in the UK","volume":"49","author":"Poole","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reumae.2021.09.002_bib0490","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/rheumatology\/keu415","article-title":"Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature","volume":"54","author":"Behrens","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reumae.2021.09.002_bib0495","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1136\/annrheumdis-2012-202035","article-title":"Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study","volume":"72","author":"Kavanaugh","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.09.002_bib0500","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1185\/03007995.2016.1140026","article-title":"An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-na\u00efve patients with psoriatic arthritis","volume":"32","author":"Betts","year":"2016","journal-title":"Curr Med Res Opin"}],"container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574321002215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574321002215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:00:36Z","timestamp":1761879636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173574321002215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S2173574321002215"],"URL":"https:\/\/doi.org\/10.1016\/j.reumae.2021.09.002","relation":{},"ISSN":["2173-5743"],"issn-type":[{"type":"print","value":"2173-5743"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2021 clinical practice guidelines for the diagnosis, treatment, and follow-up of patients with peripheral spondyloarthritis. Colombian Association of Rheumatology","name":"articletitle","label":"Article Title"},{"value":"Reumatolog\u00eda Cl\u00ednica (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reumae.2021.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.reuma.2021.09.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Reumatolog\u00eda y Colegio Mexicano de Reumatolog\u00eda. All rights reserved.","name":"copyright","label":"Copyright"}]}}